Know the market
before the deal.
TAM/SAM/SOM, competitive landscapes, partner scoring, and regulatory pathway analysis — sourced, methodology-backed, and board-presentation-ready. For biotech professionals who can't wait 3 weeks for a consulting deliverable.
KRAS G12C Inhibitor · NSCLC · Phase 2
Generated in 4.2s · ClinicalTrials.gov + FDA data · High confidence
Built by Ambrosia Ventures — life sciences M&A and strategy advisory. Our deal experience is embedded in every calculation.
Live Calculator
See your market in real time.
Pick any therapeutic area, indication, and development stage. Terrain computes TAM, SAM, SOM, and peak sales estimates instantly — the same engine powering our full intelligence reports.
- 10 therapeutic areas, 20+ indications pre-loaded
- Stage-adjusted market share modeling
- Epidemiology-driven patient funnel
- Full reports cover 15+ analytics sections
Get the full report with 15+ analytics sections — patient funnel, competitive landscape, partner matching, regulatory pathway, and deal benchmarks.
Sign up freePowered by live data pipelines
Intelligence Modules
Four modules. One platform.
Every module answers the questions that precede licensing deals, M&A transactions, and partnership discussions.
Market Sizing
Patient-funnel TAM/SAM/SOM with biomarker-specific subtypes, 10-year revenue projections, and geography breakdown. Pharma, devices, diagnostics, and nutraceuticals.
Competitive Landscape
Pipeline mapping with crowding scores, head-to-head comparisons, and deal-value context. Powered by live ClinicalTrials.gov and FDA data updated nightly.
Partner Discovery
Algorithmic matching to 300+ biopharma and medtech BD groups scored on therapeutic alignment, pipeline gaps, deal history, and financial capacity.
Regulatory Intelligence
FDA/EMA/PMDA pathway recommendation, designation eligibility, timeline benchmarking, and reimbursement strategy for drugs, devices, and diagnostics.
Why Terrain
Replace a $500K engagement with a $149/mo subscription.
Terrain delivers institutional-grade market intelligence at a fraction of the cost and time of traditional consulting — with broader coverage, real-time data, and instant updates.
Pricing
Intelligence at every scale
Start free. Upgrade when Terrain becomes indispensable.
Free
Explore the platform with core market intelligence.
- 3 market sizing reports / month
- 1 competitive landscape / month
- Limited partner discovery
- 3 saved reports
- US geography only
Pro
Full intelligence suite for active deal-makers.
14-day free trial · No credit card required
- Unlimited market sizing
- Unlimited competitive landscapes
- Full partner discovery engine
- Regulatory intelligence
- Live market intelligence feeds
- PDF & CSV export
- Global geography coverage
- Unlimited saved reports
Team
Shared intelligence for deal teams and BD groups.
- Everything in Pro
- 10 team seats included
- Shared workspace & report library
- Report folders & organization
- Team activity feed
- Collaborative annotations
- Side-by-side report comparison
- Team analytics dashboard
- Report templates
- Co-branded PDF & Excel exports
- Priority support
Enterprise
Custom intelligence infrastructure for large organizations.
- Everything in Team
- Unlimited seats
- REST API with key management
- SSO / SAML (Okta, Azure AD)
- Comprehensive audit log
- Role-based access control
- Information barriers (deal rooms)
- White-label reports
- Dedicated customer success manager
- SLA & enterprise security review
FAQ
Common questions
Five primary sources: ClinicalTrials.gov (live competitive pipeline), FDA/EMA approval databases, SEC EDGAR filings (partnership and deal disclosures, AI-extracted), WHO Global Burden of Disease (epidemiology), and a proprietary database of 10,000+ biopharma M&A and licensing transactions built by Ambrosia Ventures.
ClinicalTrials.gov data updates nightly via automated pipelines. FDA approvals and SEC EDGAR filings are processed within 24 hours. Epidemiology and pricing benchmarks are updated quarterly. Pro users get access to live market intelligence feeds with data source health dashboards.
Yes. Every output includes a methodology section and data sources footer with specific citations. The patient-funnel methodology (prevalence → diagnosed → treated → addressable → capturable) follows the same framework used by top-tier equity research analysts at Goldman Sachs and Morgan Stanley.
Yes. Terrain tracks 204 biomarkers across oncology, neurology, immunology, and other therapeutic areas. You can size markets for specific subtypes — for example, EGFR-mutant NSCLC or HER2-low breast cancer — with prevalence-adjusted patient funnels and subtype-specific competitive landscapes.
Four product categories: pharmaceuticals, medical devices (implantable, surgical, SaMD), in vitro diagnostics (IVD/CDx), and nutraceuticals. Each category uses the appropriate sizing methodology — patient funnels for drugs, procedure volumes for devices, test volumes for diagnostics — with category-specific regulatory pathways and partner databases.
Pro is for individual professionals — unlimited analyses, full module access, live market intelligence feeds, and export capabilities. Team adds 5 seats, a shared report library, API access, and a team analytics dashboard for BD groups working collaboratively.
236 indications across 18 therapeutic areas including oncology, neurology, immunology, rare disease, cardio-metabolic, GI, rheumatology, endocrinology, and more. Each indication includes detailed subtypes, biomarker profiles, standard-of-care data, and competitive intelligence.
Terrain runs on Supabase (PostgreSQL) with row-level security, encrypted at rest and in transit. Your analyses and saved reports are only visible to your account (or your team on the Team plan). We never share or sell user data.